Ontology highlight
ABSTRACT:
SUBMITTER: Treon SP
PROVIDER: S-EPMC2597120 | biostudies-literature | 2008 Dec
REPOSITORIES: biostudies-literature
Treon Steven P SP Soumerai Jacob D JD Branagan Andrew R AR Hunter Zachary R ZR Patterson Christopher J CJ Ioakimidis Leukothea L Briccetti Frederick M FM Pasmantier Mark M Zimbler Harvey H Cooper Robert B RB Moore Maria M Hill John J Rauch Alan A Garbo Lawrence L Chu Luis L Chua Cynthia C Nantel Stephen H SH Lovett David R DR Boedeker Hans H Sonneborn Henry H Howard John J Musto Paul P Ciccarelli Bryan T BT Hatjiharissi Evdoxia E Anderson Kenneth C KC
Blood 20080819 12
Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m(2) per week) dosed on weeks 2 to 5 and 13 to 16. Twenty-five patients were enrolled, 20 of whom were untreated. Responses were complete res ...[more]